Cytomia Injection 100 mg/vial contains Cytarabine, a highly effective chemotherapeutic agent primarily used in the treatment of blood-related cancers. Cytarabine belongs to the class of antimetabolite drugs, which inhibit DNA synthesis and prevent the rapid proliferation of cancer cells. It is widely utilized in the management of acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML) in blast crisis, and certain types of non-Hodgkin’s lymphoma.

Cytomia Injection 100 mg is intended for intravenous administration, typically under strict hospital or clinical supervision. Its formulation ensures precise dosing and reliable delivery of the active compound to the bloodstream, allowing effective penetration into the bone marrow where leukemic cells proliferate.

Cytarabine is particularly effective against rapidly dividing cancer cells, making Cytomia a critical component of induction, consolidation, and maintenance chemotherapy regimens for hematologic malignancies.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Mechanism of Action

Cytarabine is a pyrimidine nucleoside analog that mimics cytidine, a natural nucleoside used in DNA synthesis. Once inside the cell, Cytarabine is phosphorylated into its active triphosphate form (ara-CTP), which competes with natural nucleotides during DNA replication.

Incorporation of ara-CTP into the DNA chain leads to premature termination of DNA synthesis, disrupting the replication process and triggering apoptosis (programmed cell death) in rapidly dividing leukemic cells.

Because healthy cells divide at a slower rate than malignant cells, Cytomia selectively targets cancerous tissues while minimizing damage to most normal cells.

Indications

Cytomia Injection 100 mg/vial is primarily indicated for:

• Acute myeloid leukemia (AML) – induction and consolidation therapy

• Acute lymphoblastic leukemia (ALL)

• Chronic myeloid leukemia (CML) in blast crisis

• Non-Hodgkin’s lymphoma (specific subtypes)

• Part of combination chemotherapy regimens for hematologic malignancies

It is often administered in combination with other chemotherapeutic agents to improve efficacy and achieve better remission rates.

Dosage and Administration

The dosage of Cytomia Injection depends on the type of leukemia, patient body surface area (BSA), age, and overall health. It is administered intravenously, either as a slow infusion or continuous infusion, depending on the specific treatment protocol.

Patients require close monitoring of blood counts, liver and kidney function, and overall health status during therapy. Dose adjustments may be necessary in cases of severe toxicity, organ impairment, or infection.

Precautions and Warnings

• Administer only under professional supervision in a hospital or clinical setting.

• Patients with liver or kidney disease, infections, or low blood counts require careful monitoring.

• Cytarabine can cause fetal harm; pregnancy should be avoided during therapy.

• Patients may experience immunosuppression, increasing susceptibility to infections.

• Healthcare personnel must use protective equipment while handling the drug, as it is cytotoxic.

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Possible Side Effects

Common side effects include:

• Nausea and vomiting

• Fatigue and weakness

• Bone marrow suppression leading to low white blood cells, red blood cells, and platelets

• Fever, chills, or infections

• Mouth sores or gastrointestinal irritation

• Rare cases of liver or kidney dysfunction, neurological symptoms, or severe allergic reactions

Supportive care, hydration, and regular monitoring are essential to minimize side effects.

Storage Instructions

Store Cytomia Injection 100 mg/vial in a cool, dry place, protected from light. Keep out of reach of children. Reconstituted or diluted solutions should be prepared and administered immediately according to hospital protocols.

Cytomia Injection 100 mg/vial is a vital chemotherapeutic agent, providing targeted antileukemic activity and playing a key role in the management of hematologic malignancies.